Biotech Values

[iandy]

GRTS - Possible rationale for a second dose of samRNA


Gritstone is hoping to establish efficacy and durability of response against current and future mutations of Covid-19. Chances are we will see further major mutations.

The second (or booster) might spur the immune system to ramp up the quality and quantity of antibodies necessary to achieve the desired effect.

>ARMS AND INTERVENTIONS

Experimental:
Cohort 1: 2 Doses 10 mcg GRT-R910 after AstraZeneca Standard of Care
Participants (including 2 sentinels) receive 2 doses of 10 mcg GRT-R910 homologous prime-boost (after AstraZeneca standard of care).
Biological: Intervention type: GRT-R910 booster 113 days after prime
10 mcg or 30 mcg prime vaccine by intramuscular (IM) injection on Day 1 and 10 mcg or 30 mcg boost by IM injection 113 days later.
Experimental:
Cohort 2: 2 Doses 30 mcg GRT-R910 after AstraZeneca Standard of Care
Participants (including 2 sentinels) receive 2 doses of 30 mcg GRT-R910 homologous prime-boost (after AstraZeneca standard of care).
Biological: Intervention type: GRT-R910 booster 113 days after prime
10 mcg or 30 mcg prime vaccine by intramuscular (IM) injection on Day 1 and 10 mcg or 30 mcg boost by IM injection 113 days later.
Experimental:
Cohort 3: 2 Doses 10 mcg or 30 mcg GRT-R910 after Adenovirus-Based Vector Vaccine Standard of Care
Participants receive 2 doses of 10 mcg or 30 mcg GRT-R910 homologous prime-boost (after adenovirus-based vector vaccine standard of care).
Experimental:
Cohort 4: 2 Doses 10 mcg or 30 mcg GRT-R910 after mRNA Vaccine Standard of Care
Participants receive 2 doses of 10 mcg or 30 mcg GRT-R910 homologous prime-boost (after mRNA vaccine standard of care).<

https://beta.clinicaltrials.gov/study/NCT05148962?patient=Gritstone%20Covid%2019&locStr=&distance=0